Sunshine Biopharma Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| SUNSHINE BIOPHARMA, INC. | ||
| Dated: March 28, 2024 | By: | /s/ Dr. Steve N. Slilaty |
|---|---|---|
| Dr. Steve N. Slilaty, Chief Executive Officer (principal executive officer) | ||
| /s/ Camille Sebaaly | ||
| Camille Sebaaly, Chief Financial Officer (principal financial and accounting officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Dr. Steve N. Slilaty | Chief Executive Officer and Director | March 28, 2024 |
| Dr. Steve N. Slilaty | (Principal Executive Officer) | |
| /s/ Camille Sebaaly | Chief Financial Officer | March 28, 2024 |
| Camille Sebaaly | (Principal Financial and Accounting Officer) | |
| /s/ Dr. Abderrazzak Merzouki | Director | March 28, 2024 |
| Dr. Abderrazzak Merzouki | ||
| /s/ David Natan | Director | March 28, 2024 |
| David Natan | ||
| /s/ Dr. Andrew Keller | Director | March 28, 2024 |
| Dr. Andrew Keller | ||
| /s/ Dr. Rabi Kiderchah | Director | March 28, 2024 |
| Dr. Rabi Kiderchah | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.